ACST - アカスティ・ファ―マ (Acasti Pharma Inc.)

ACSTのニュース

  Acasti PharmaがTRILOGY 1フェーズ3トライアルを更新 Acasti Pharma Updates on TRILOGY 1 Phase 3 Trial  2019/11/26 16:56:36 Investing News Network
「同社は、CaPreのTRILOGY 1の極めて重要な第3相臨床試験で最後の患者が最後の訪問を完了したと発表しました。
The company announced that the last patient completed their final visit in its TRILOGY 1 pivotal Phase 3 clinical trial of CaPre. The post Acasti Pharma Updates on TRILOGY 1 Phase 3 Trial appeared first on Investing News Network .
   Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc.  2019/11/25 13:30:00 Yahoo Finance
Dover, Delaware--(Newsfile Corp. - November 25, 2019) - Encode Ideas, L.P. Initiates Research on Acasti Pharma, Inc. (NASDAQ: ACST). The full research publication is available here and available on our website at www.encodelp.com. Encode Ideas is initiating coverage on Acasti Pharma, Inc. as a high-risk
   Acasti Pharma Releases Preliminary Data for CaPre in Diabetic Mice  2019/11/18 23:30:13 Investing News Network
According to the announcement, CaPre demonstrated insulin secretion, which its counterpart metformin is not able to do. The post Acasti Pharma Releases Preliminary Data for CaPre in Diabetic Mice appeared first on Investing News Network .
   Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal  2019/11/07 13:30:00 Yahoo Finance
LAVAL, Québec, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of
   Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference  2019/10/01 13:00:00 Yahoo Finance
LAVAL, Québec, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of
   Acasti Pharma's (ACST) CEO Jan D'Alvise on Q2 2018 Results - Earnings Call Transcript  2018-11-14
Acasti Pharma, Inc. (ACST) Q2 2018 Earnings Conference Call November 14, 2018, 11:00 ET Executives David Waldman - IR Jan D'Alvise - President and CEO Pierre Lemieux - Chief Operating Officer, Chief Scientific Officer and Co-Founder Brian Groach - Chief Commercial Officer Jea…

calendar